Arden stock registration
This article was originally published in The Rose Sheet
Executive Summary
Fragrance marketer files registration statement with Securities and Exchange Commission for up to $125 mil. in common stock that may be sold in one or more offerings. Arden currently has no immediate plans to sell its stock but "intends to evaluate market conditions over time." Proceeds would be used for general corporate purposes, including the repayment of debt," company says. Additional 1.4 mil. shares included in the statement are owned by Unilever subsidiary Conopco and represent the vested portion of company's 4.2 mil. shares of common stock issued in conjunction with the Elizabeth Arden acquisition from Unilever...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.